SCHEMBL6430080

SCHEMBL6430080

CC(C)(CCCC[S+]([O-])CCCCC(C)(CO)c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
SIGMAR1 Q99720 1/20 0.31
CNR1 P21554 1/20 0.30
CNR2 P34972 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6429686 0.96 CYP2C19 (0.37) CYP2C19HIF1ATAAR1LMNA
SCHEMBL5518734 0.94 CYP2C19 (0.40) CYP2C19HIF1ATAAR1SIGMAR1LMNA
SCHEMBL6505272 0.93 CYP2C19 (0.39) CYP2C19HIF1ATAAR1SIGMAR1LMNA
SCHEMBL5526988 0.90 CYP2C19 (0.41) CYP2C19HIF1ATAAR1SIGMAR1LMNA
SCHEMBL6698317 0.84 CYP2C19 (0.39) CYP2C19HIF1A
SCHEMBL6709897 0.84 CYP2C19 (0.39) CYP2C19HIF1ATAAR1SIGMAR1LMNA
SCHEMBL6509759 0.84 CYP2C19 (0.39) CYP2C19HIF1ATAAR1SIGMAR1CNR1
SCHEMBL6700913 0.83 CYP2C19 (0.38) CYP2C19HIF1A
SCHEMBL6503988 0.82 CYP2C19 (0.38) CYP2C19HIF1ATAAR1SIGMAR1LMNA
SCHEMBL6530675 0.82 CYP2C19 (0.38) CYP2C19HIF1ATAAR1SIGMAR1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002030882-A9 SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS INC (US) 2003-02-20 WO claimed
EP-1539127-A1 METHOD OF TREATING OSTEOARTHRITIS WARNER-LAMBERT COMPANY LLC (US) 2005-06-15 EP disclosed
WO-2004017952-A1 METHOD OF TREATING OSTEOARTHRITIS WARNER-LAMBERT COMPANY LLC (US) 2004-03-04 WO disclosed